The hypothesis of this proposal for a CIA is that excessive dopamine release in the neostriatum may contribute to the cerebral damage incurred in neonatal hypoxic-ischemic encephalopathy. This is based on recent studies indicating that CNS ischemia is accompanied by a 30-fold increase in extracellular dopamine which, in these circumstances, May be neurotoxic. Two phases of study are proposed. In vivo studies (phase 1) will utilize a neonatal rat model. Neurochemical and histologic methods (including GFAP immunocytochemistry, calculation of striatal area and volume, autoradiography of dopamine DI receptors and of peripheral benzodiazepine binding sites) will be employed to quantitate the degree and extent of brain damage. The potential neuroprotective effects of a depleter of endogenous dopamine (alpha-methyl-ptyrosine), of dopamine antagonists, both non-selective (fluphenazine and flupenthioxl) and selective (SCH 23390; sulpiride), and of antioxidants will be assessed in this model. Mechanisms of dopamine-induced neuronal damage will next be examined (%phase 2"""""""") in vitro using striatal tissue culture to determine if dopamine-induced brain injury is mediated through stimulation of specific receptors, or through the generation of oxygen free radicals. The ability of dopamine antagonists versus free radical scavengers to protect neurons in culture from excess dopamine will be determined. The results of the proposed research should contribute to the understanding of the pathophysiology of CNS injury in neonatal hypoxic-ischemia, and may suggest therapeutic interventions in the human neonate. Dr. Filloux will be supervised in this research endeavor by Dr. Thomas N. Parks, a well-known, respected developmental neurobiologist with documented expertise in excitotoxic cellular effects and in CNS tissue culture techniques. All the laboratory space and equipment as well as ancillary assistance necessary for the successful completion of this project will be made available to Dr. Filloux by Dr. Parks and through the unified support of the Departments of Pediatrics, Neurology, and Psychiatry at the University of Utah.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HD000912-03
Application #
3081443
Study Section
Mental Retardation Research Committee (HDMR)
Project Start
1990-08-01
Project End
1993-07-31
Budget Start
1992-08-01
Budget End
1993-07-31
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Kim, So Youn; Weinstein, David A; Starost, Matthew F et al. (2008) Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. J Hepatol 48:479-85
Yiu, W H; Pan, C-J; Ruef, R A et al. (2008) Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int 73:716-23
Chou, Janice Y; Mansfield, Brian C (2008) Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 29:921-30
Yiu, W H; Pan, C-J; Allamarvdasht, M et al. (2007) Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther 14:219-26
Chou, Janice Y; Mansfield, Brian C (2007) Gene therapy for type I glycogen storage diseases. Curr Gene Ther 7:79-88
Kim, So Youn; Chen, Li-Yuan; Yiu, Wai Han et al. (2007) Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Lett 581:3833-8
Walker, Elizabeth A; Ahmed, Adeeba; Lavery, Gareth G et al. (2007) 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. J Biol Chem 282:27030-6
Filloux, F M; Adair, J; Narang, N (1996) The temporal evolution of striatal dopamine receptor binding and mRNA expression following hypoxia-ischemia in the neonatal rat. Brain Res Dev Brain Res 94:81-91
Filloux, F; Schapper, A; Naisbitt, S R et al. (1994) Complex patterns of [125I]omega-conotoxin GVIA binding site expression during postnatal rat brain development. Brain Res Dev Brain Res 78:131-6
Johnson, M; Hanson, G R; Gibb, J W et al. (1994) Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats. Brain Res Dev Brain Res 83:109-18

Showing the most recent 10 out of 17 publications